• Je něco špatně v tomto záznamu ?

Engineered Lactococcus lactis Secreting IL-23 Receptor-Targeted REX Protein Blockers for Modulation of IL-23/Th17-Mediated Inflammation

TV. Plavec, M. Kuchař, A. Benko, V. Lišková, J. Černý, A. Berlec, P. Malý,

. 2019 ; 7 (5) : . [pub] 20190527

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc19028963

Grantová podpora
16-27676A Czech Health Research Council, Ministry of Health of the Czech Republic
SAZU-16-01 Czech Academy of Sciences (CAS) and Slovenian Academy of Sciences and Arts (SAZU)
RVO: 86652036 Institutional Research Concept
BIOCEV CZ.1.05/1.1.00/02.0109 European Regional Development Fund
P4-0127 and J4-9327 Slovenian Research Agency (ARRS)
NV16-27676A MZ0 CEP - Centrální evidence projektů

Lactococcus lactis, a probiotic bacterium of food origin, has recently been demonstrated as a suitable strain for the production and in vivo delivery of therapeutically important proteins into the gut. We aimed to engineer recombinant L. lactis cells producing/secreting REX binding proteins that have been described as IL-23 receptor (IL-23R) blockers and IL-23R antagonists suppressing the secretion of cytokine IL-17A, a pivotal step in the T-helper Th17-mediated pro-inflammatory cascade, as well as in the development of autoimmune diseases, including inflammatory bowel disease (IBD). To reach this goal, we introduced cDNA sequences coding for REX009, REX115, and REX125 proteins into plasmid vectors carrying a Usp45 secretion signal, a FLAG tag sequence consensus, and a LysM-containing cA surface anchor (AcmA), thus allowing cell-surface peptidoglycan anchoring. These plasmids, or their non-FLAG/non-AcmA versions, were introduced into L. lactis host cells, thus generating unique recombinant L. lactis-REX strains. We demonstrate that all three REX proteins are expressed in L. lactis cells and are efficiently displayed on the bacterial surface, as tested by flow cytometry using an anti-FLAG antibody conjugate. Upon 10-fold concentration of the conditioned media, a REX125 secretory variant can be detected by Western blotting. To confirm that the FLAG/non-FLAG REX proteins displayed by L. lactis retain their binding specificity, cell-surface interactions of REX proteins with an IL-23R-IgG chimera were demonstrated by flow cytometry. In addition, statistically significant binding of secreted REX009 and REX115 proteins to bacterially produced, soluble human IL-23R was confirmed by ELISA. We conclude that REX-secreting L. lactis strains were engineered that might serve as IL-23/IL-23R blockers in an experimentally induced mouse model of colitis.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19028963
003      
CZ-PrNML
005      
20210310102511.0
007      
ta
008      
190813s2019 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/microorganisms7050152 $2 doi
035    __
$a (PubMed)31137908
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Plavec, Tina Vida $u Department of Biotechnology, Jožef Stefan Institute, Jamova 39, SI-1000 Ljubljana, Slovenia. tina.plavec@ijs.si. Faculty of Pharmacy, University of Ljubljana, Aškerčeva 7, SI-1000 Ljubljana, Slovenia. tina.plavec@ijs.si.
245    10
$a Engineered Lactococcus lactis Secreting IL-23 Receptor-Targeted REX Protein Blockers for Modulation of IL-23/Th17-Mediated Inflammation / $c TV. Plavec, M. Kuchař, A. Benko, V. Lišková, J. Černý, A. Berlec, P. Malý,
520    9_
$a Lactococcus lactis, a probiotic bacterium of food origin, has recently been demonstrated as a suitable strain for the production and in vivo delivery of therapeutically important proteins into the gut. We aimed to engineer recombinant L. lactis cells producing/secreting REX binding proteins that have been described as IL-23 receptor (IL-23R) blockers and IL-23R antagonists suppressing the secretion of cytokine IL-17A, a pivotal step in the T-helper Th17-mediated pro-inflammatory cascade, as well as in the development of autoimmune diseases, including inflammatory bowel disease (IBD). To reach this goal, we introduced cDNA sequences coding for REX009, REX115, and REX125 proteins into plasmid vectors carrying a Usp45 secretion signal, a FLAG tag sequence consensus, and a LysM-containing cA surface anchor (AcmA), thus allowing cell-surface peptidoglycan anchoring. These plasmids, or their non-FLAG/non-AcmA versions, were introduced into L. lactis host cells, thus generating unique recombinant L. lactis-REX strains. We demonstrate that all three REX proteins are expressed in L. lactis cells and are efficiently displayed on the bacterial surface, as tested by flow cytometry using an anti-FLAG antibody conjugate. Upon 10-fold concentration of the conditioned media, a REX125 secretory variant can be detected by Western blotting. To confirm that the FLAG/non-FLAG REX proteins displayed by L. lactis retain their binding specificity, cell-surface interactions of REX proteins with an IL-23R-IgG chimera were demonstrated by flow cytometry. In addition, statistically significant binding of secreted REX009 and REX115 proteins to bacterially produced, soluble human IL-23R was confirmed by ELISA. We conclude that REX-secreting L. lactis strains were engineered that might serve as IL-23/IL-23R blockers in an experimentally induced mouse model of colitis.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kuchař, Milan $u Laboratory of Ligand Engineering, Institute of Biotechnology of the Czech Academy of Sciences, v. v. i., BIOCEV Research Center, Průmyslová 595, 252 50 Vestec, Czech Republic. milan.kuchar@ibt.cas.cz.
700    1_
$a Benko, Anja $u Department of Biotechnology, Jožef Stefan Institute, Jamova 39, SI-1000 Ljubljana, Slovenia. benko.anja@gmail.com. Faculty of Pharmacy, University of Ljubljana, Aškerčeva 7, SI-1000 Ljubljana, Slovenia. benko.anja@gmail.com.
700    1_
$a Lišková, Veronika $u Laboratory of Ligand Engineering, Institute of Biotechnology of the Czech Academy of Sciences, v. v. i., BIOCEV Research Center, Průmyslová 595, 252 50 Vestec, Czech Republic. veronika.liskova@ibt.cas.cz.
700    1_
$a Černý, Jiří $u Laboratory of Structural Bioinformatics of Proteins, Institute of Biotechnology of the Czech Academy of Sciences, v. v. i., BIOCEV Research Center, Průmyslová 595, 252 50 Vestec, Czech Republic. jiri.cerny@ibt.cas.cz.
700    1_
$a Berlec, Aleš $u Department of Biotechnology, Jožef Stefan Institute, Jamova 39, SI-1000 Ljubljana, Slovenia. ales.berlec@ijs.si. Faculty of Pharmacy, University of Ljubljana, Aškerčeva 7, SI-1000 Ljubljana, Slovenia. ales.berlec@ijs.si.
700    1_
$a Malý, Petr $u Laboratory of Ligand Engineering, Institute of Biotechnology of the Czech Academy of Sciences, v. v. i., BIOCEV Research Center, Průmyslová 595, 252 50 Vestec, Czech Republic. petr.maly@ibt.cas.cz.
773    0_
$w MED00198767 $t Microorganisms $x 2076-2607 $g Roč. 7, č. 5 (2019)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31137908 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190813 $b ABA008
991    __
$a 20210310102507 $b ABA008
999    __
$a ind $b bmc $g 1434112 $s 1067423
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 7 $c 5 $e 20190527 $i 2076-2607 $m Microorganisms $n Microorganisms $x MED00198767
GRA    __
$a 16-27676A $p Czech Health Research Council, Ministry of Health of the Czech Republic
GRA    __
$a SAZU-16-01 $p Czech Academy of Sciences (CAS) and Slovenian Academy of Sciences and Arts (SAZU)
GRA    __
$a RVO: 86652036 $p Institutional Research Concept
GRA    __
$a BIOCEV CZ.1.05/1.1.00/02.0109 $p European Regional Development Fund
GRA    __
$a P4-0127 and J4-9327 $p Slovenian Research Agency (ARRS)
GRA    __
$a NV16-27676A $p MZ0
LZP    __
$a Pubmed-20190813

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...